Patients with obstructive sleep apnea who used the Inspire upper airway stimulation implant had fewer heart attacks and strokes compared to those who went untreated, according to findings presented at the SLEEP 2026 conference. The results come from the PREDICTOR study, which Inspire Medical Systems published alongside its presence at the annual meeting.
According to a report by The Manila Times, Inspire Medical Systems announced both its participation at SLEEP 2026 and the publication of the PREDICTOR study at the same time. The study examined whether the implantable device, which stimulates the airway during sleep to prevent obstruction, had measurable effects on serious cardiovascular events in patients diagnosed with obstructive sleep apnea.
Obstructive sleep apnea is a condition in which the airway repeatedly collapses during sleep, causing brief interruptions in breathing. It affects tens of millions of people and has long been associated with elevated risk of heart disease, stroke, and other cardiovascular problems. Many patients who receive a diagnosis either cannot tolerate the standard treatment, a continuous positive airway pressure machine, or do not use it consistently.
The Inspire device works differently from a CPAP machine. It is surgically implanted and delivers mild electrical stimulation to the hypoglossal nerve, which controls tongue movement, keeping the airway open during sleep. Patients activate it with a small handheld remote before going to bed.
Stock Titan reported that the PREDICTOR study linked use of the Inspire implant to a reduction in major cardiovascular events. The findings add to a growing body of research suggesting that effectively treating sleep apnea may reduce the downstream risks associated with the condition, including heart attack and stroke.
The SLEEP 2026 conference draws researchers and clinicians from across the field of sleep medicine. Inspire Medical Systems used the event to highlight the new data, which the company said supports the broader cardiovascular benefit of treating obstructive sleep apnea with upper airway stimulation rather than leaving the condition unmanaged.
Inspire Medical Systems has been expanding the evidence base for its device in recent years. The PREDICTOR study publication marks one of the more direct examinations of whether the implant affects hard cardiovascular outcomes, rather than focusing solely on sleep quality measures or apnea severity scores, which have historically been the primary endpoints in sleep apnea research.
